MitoQ

Rubedo collaborates with Cedars-Sinai on senolytic IPF program

Latest articles

Drive to end cancer could pioneer diagnostic technology

Blood test that can determine a cancer signal origin with high accuracy is now available on prescription in the US and could lead to...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

Improving speed and accuracy in Alzheimer’s patients

Phase 2a study of patients with Alzheimer's or Parkinson's finds that ANVS401 treatment leads to significant improvement in speed and accuracy. Annovis Bio Inc, a...

New SIRT6 activator supplement hits the market

Sirtuin 6, the protein making waves in the longevity pool, can now be activated by a brand-new supplement. SIRT6 is a protein with an important...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...
fundraising

Editor's picks

Drive to end cancer could pioneer diagnostic technology

Blood test that can determine a cancer signal origin with high accuracy is now available on prescription in the US and could lead to...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

Improving speed and accuracy in Alzheimer’s patients

Phase 2a study of patients with Alzheimer's or Parkinson's finds that ANVS401 treatment leads to significant improvement in speed and accuracy. Annovis Bio Inc, a...
MitoQ

Click the globe for translations.

Senolytic start-up establishes collaboration with Cedars-Sinai Medical Center to advance idiopathic pulmonary fibrosis program.

Silicon Valley start-up Rubedo Life Sciences today announced a collaboration with Cedars-Sinai Medical Center in Los Angeles, to advance its idiopathic pulmonary fibrosis (IPF) senolytic theraputics program and establish collaborative studies. As part of the collaboration, Dr Cory Hogaboam, professor of medicine and research scientist at Cedars-Sinai will be joining Rubedo’s Scientific Advisory Board.

Longevity.Technology: Affecting around 100,000 people in the US, IPF is a rare, but serious lung disease that causes a build-up of scar tissue in the lungs. When we spoke with Rubedo earlier this year, CEO Dr Marco Quarta expressed concern that the COVID-19 pandemic may lead to a surge in IPF cases, and that he hoped to bring a therapeutic to the clinic “as soon as possible”.

Rubedo’s main program targets senescent cells, which accumulate in multiple tissues in our bodies as we age and promote inflammation, fibrosis and cancer. Cellular senescence is a master regulator of aging and drives many age-related diseases.

Marco Quarta
CEO, Rubedo Life Sciences, Dr Marco Quarta

“Rubedo’s strategy for entry into the longevity space is a senolytic program, targeting the pro inflammatory and pro fibrotic senescent cells,” said Quarta in a statement. “Our first clinical program will be IPF, which is an unmet medical need and we look forward to working with Cedars Sinai Medical Center.”

Taking senolytics to the clinic

Commenting on today’s news, Quarta told us, “Together with the team at Cedars-Sinai we are building an innovative pipeline that will allow to solidly advance Rubedo’s therapeutic discovery program for IPF into the clinic.

“We are excited to work with world-class experts in interstitial lung diseases at Cedars-Sinai. In particular, Professor Hogaboam is a fantastic advisor and collaborator. He brings a deep understanding of IPF pathology, the clinical landscape but also of cellular senescence and its role in IPF disease.”

Unique among senolytic therapies

Dr Hogaboam’s distinguished career encompasses more than 20 years of scientific experience and he is also an adjunct professor of pathology at the University of Michigan Medical School.

“I joined forces advising and collaborating with Rubedo because throughout my career working on IPF, I came to the conclusion that targeting cellular senescence is the only way to unlock a possible cure for this devastating age-related disease,” he said. “Among all the proposed senolytic therapies, Rubedo has a unique platform that promises to successfully deliver an effective pharmacological treatment for IPF.”

Rubedo’s proprietary Alembic drug discovery platform combines computational and chemistry proprietary technologies to generate novel prodrugs that selectively target multiple pathologic cell types (including rare cell types) driving age-related diseases.

We are currently preparing our market intelligence report on senotherapeutics and senolytics which is available for pre-order now.

Image courtesy of Rubedo Life Sciences

Comment on this article

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
MitoQ

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
fundraising

Related articles

Improving speed and accuracy in Alzheimer’s patients

Phase 2a study of patients with Alzheimer's or Parkinson's finds that ANVS401 treatment leads to significant improvement in speed and accuracy. Annovis Bio Inc, a...

Brinter accelerates 3D bioprinting with €1.2m seed fund

Modular multi-material 3D bioprinting solution hopes to develop cost-effective answer to global need for kidney transplants. Turku-based bioprinting start-up Brinter has today announced the successful closure...

Occuity – shining a light on health and longevity

Forget windows to the soul, Occuity's non-invasive smart diagnostic tech provides a window to health and wellness. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited)...

Biogen wins FDA approval for Alzheimer’s drug aducanumab

Landmark decision means Alzheimer's research is moving past a bottleneck, with first new drug in 18 years. After two years of back-and-forth, the FDA has...

Research increases mice life expectancy by 30%

Bar-Ilan University researchers increase life expectancy in mice with protein SIRT6. The "fountain of youth" allows old mice to conduct the same level of...
Supps report ad middle